ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1100

Racial Differences in Clinical Trial Perceptions Among a Large, Predominantly Black Cohort of Patients with Systemic Lupus Erythematosus in the Southeastern United States

Jessica Williams1, Gaobin Bao1, Charmayne Dunlop-Thomas2, Cristina Drenkard2, Kim Schofield1 and S. Sam Lim2, 1Emory University School of Medicine, Atlanta, GA, 2Emory University, Atlanta, GA

Meeting: ACR Convergence 2022

Keywords: Disparities, Minority Health, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Healthcare Disparities in Rheumatology

Session Type: Abstract Session

Session Time: 10:30AM-11:30AM

Background/Purpose: Black patients have higher incidence and severity of systemic lupus erythematosus (SLE) and worse outcomes as compared to White patients, yet Black patients are significantly underrepresented in SLE clinical trials. We assessed racial differences in clinical trial perceptions among the largest cohort of predominantly Black patients with SLE ever assembled in the United States.

Methods: Georgians Organized Against Lupus (GOAL) is a prospective cohort of validated patients with SLE living in Atlanta. Participants have been surveyed annually since 2012 regarding demographics, SLE natural history, treatment, healthcare utilization, and psychosocial factors. The 2021 GOAL survey included questions assessing clinical trial knowledge, trustworthy sources of trial information, prior experience with trial recruitment/participation, willingness to participate in trials, and the impact of race and gender on participation. Self-reported race was categorized as Black or Non-Black. Survey responses by race were compared using Chi-squared analyses. Among Black patients, factors associated with willingness to participate in clinical trials were examined using univariable logistic regression.

Results: A total of 708 individuals responded to the 2021 GOAL survey, of whom 80% were Black. Among the remaining 20%, 88% were White, 11% were Asian, and 1% were another race. Compared to non-Black respondents, Black respondents were significantly less likely to correctly identify the definition of a clinical trial (34% vs. 72%, p< 0.001) and less likely to trust their rheumatologist about clinical trial information (90 vs. 96%, p=0.034); Table 1. Black respondents were significantly more likely to trust their lupus support group about clinical trial information (26% vs. 11%, p< 0.001) and to prefer clinical trials involving study staff with racial (24% vs. 10%, p< 0.001) and gender concordance (21% vs. 14%, p< 0.001), as well as trials targeting the respondent’s racial (30% vs. 12%, p< 0.001) or gender group (26% vs. 20%, p< 0.001). There was no significant difference in willingness to participate in clinical trials between Black and non-Black respondents (28% vs. 30%, p=0.10). Younger age, male sex, unemployed or disabled status, federal health insurance, higher disease activity, and severe damage were associated with willingness to participate in clinical trials among Black respondents (Table 2).

Conclusion: We found that only about 30% of respondents were willing to participate in lupus clinical trials, with similar willingness to participate among Black and non-Black respondents. Efforts must continue to engage those resistant to trial participation. Our findings also indicate that clinical trial education, recruitment through lupus support groups, increased racial and gender diversity of study staff, and race- and gender-specific trials are potential strategies to increase Black patient recruitment. Age, sex, work status, insurance status, and lupus activity and damage may also play important roles in clinical trial participation among Black patients. Further studies are needed to validate these findings in other large populations of Black patients with SLE.

Supporting image 1

Supporting image 2

Supporting image 3

*Two patients excluded due to missing responses. **Defined as a response of always, usually, or sometimes on the IPC_29: Interpersonal Processes of Care Survey. OR=odds ratio; CI=confidence interval; ref=reference; SLAQ=Systemic Lupus Activity Questionnaire; BILD=Brief Index of Lupus Damage; PROMIS-SF= Patient Reported Outcome Measurement Information System-Short Form.


Disclosures: J. Williams, None; G. Bao, None; C. Dunlop-Thomas, None; C. Drenkard, None; K. Schofield, None; S. Lim, None.

To cite this abstract in AMA style:

Williams J, Bao G, Dunlop-Thomas C, Drenkard C, Schofield K, Lim S. Racial Differences in Clinical Trial Perceptions Among a Large, Predominantly Black Cohort of Patients with Systemic Lupus Erythematosus in the Southeastern United States [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/racial-differences-in-clinical-trial-perceptions-among-a-large-predominantly-black-cohort-of-patients-with-systemic-lupus-erythematosus-in-the-southeastern-united-states/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/racial-differences-in-clinical-trial-perceptions-among-a-large-predominantly-black-cohort-of-patients-with-systemic-lupus-erythematosus-in-the-southeastern-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology